单克隆抗体治疗系统性红斑狼疮的临床研究进展  

Progress in clinical research on monoclonal antibodies for treatment of systemic lupus erythematosus

作　　者：杨先远(综述) 王红胜(审校)[1] YANG Xian-yuan;WANG Hong-sheng(School of Pharmaceutical Sciences,Sun Yat-Sen University,Guangzhou 510006,Guangdong Province,China)

机构地区：[1]中山大学药学院,广东广州510006

出　　处：《中国生物制品学杂志》2021年第12期1511-1515,共5页Chinese Journal of Biologicals

基　　金：国家自然基金面上项目(81973343)。

摘　　要：系统性红斑狼疮(systemic lupus erythematosus,SLE)是一种累及全身的慢性自身免疫疾病,可对多器官造成损害。随着对SLE发生发展分子机制的深入研究,发现了许多与SLE发生发展相关的靶点分子,如B淋巴细胞刺激因子(B lymphocyte stimulator,BLyS)、B淋巴细胞表面的CD20受体及CD22受体、T淋巴细胞表面的CD80受体及CD86受体、干扰素α(interferonα,IFNα)及其受体、白细胞介素-6(interleukin-6,IL-6)、IL-12、IL-23、肿瘤坏死因子-α(tumor necrosis factor-α,TNF-α),其中一些相应单克隆抗体已进入临床试验阶段或已上市,用于治疗SLE。本文对已进行Ⅱ或Ⅲ期临床试验的SLE相关靶点分子单克隆抗体的部分试验结果作一综述。Systemic lupus erythematosus(SLE)is an autoimmune disease which damages various organs.With the increasing researches on the mechanism of SLE,various target molecules associated with the onset and progress of SLE,such as B lymphocyte stimulator(BLyS),CD20 and CD22 receptors on surface of B lymphocytes,CD80 and CD86 receptors on surface of T lymphocytes,interferon(IFN)αand its receptor,interleukin(IL)-6,IL-12,IL-23 and tumor necrosis factor-αhave been discovered,against which some monoclonal antibodies(McAbs)have been in clinical trials or have entered to the market and used for the treatment of SLE.This paper reviews partial results of phaseⅡorⅢclinical trials on McAbs against the SLE-associated target molecules.

关 键 词：系统性红斑狼疮 单克隆抗体 临床试验 

分 类 号：R593.241[医药卫生—内科学]